Mutations in TRiC subunit genes were found in nearly half of HCC patients, including CCT3 mutations in 27%, CCT5 mutations in 18%, and TCP1 mutations in 12%, and patients harboring such CCT gene mutations demonstrated poorer clinical outcome compared to patients without mutations. This evidence concerns the gene MARVELD2 and hepatocellular carcinoma.